4.4 Review

The Synucleinopathies: Twenty Years On

期刊

JOURNAL OF PARKINSONS DISEASE
卷 7, 期 -, 页码 S53-S71

出版社

IOS PRESS
DOI: 10.3233/JPD-179005

关键词

Alpha-synuclein; Parkinson's disease; dementia with Lewy bodies; multiple system atrophy; protein aggregation; aggregate propagation; neurodegeneration

资金

  1. UK Medical Research Council [MC_U105184291]
  2. EU Joint Programme - Neurodegenerative Disease Research
  3. UK Medical Research Council
  4. Alzheimer's Research UK
  5. Gates International
  6. Astra Zeneca
  7. Cambridge Biomedical Centre
  8. Addenbrooke's Hospital Trust
  9. National Centre for the Replacement, Refinement and Reduction of Animals in Research
  10. Medical Research Council [MC_U105184291] Funding Source: researchfish
  11. Parkinson's UK [G-1102] Funding Source: researchfish
  12. The Cure Parkinsons Trust [CPT11] Funding Source: researchfish
  13. MRC [MC_U105184291] Funding Source: UKRI

向作者/读者索取更多资源

In 2017, it is two hundred years since James Parkinson provided the first complete clinical description of the disease named after him, fifty years since the introduction of high-dose D,L-DOPA treatment and twenty years since alpha-synuclein aggregation came to the fore. In 1998, multiple system atrophy joined Parkinson's disease and dementia with Lewy bodies as the third major synucleinopathy. Here we review our work, which led to the identification of alpha-synuclein in Lewy bodies, Lewy neurites and Papp-Lantos bodies, as well as what has happened since. Some of the experiments described were carried out in collaboration with ML Schmidt, JQ Trojanowski and VMY Lee.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据